OBJECTIVE： To analyze the correlation between ac- he and Northwest dryness syndrome in the Xinji- ang region to provide an epidemiological founda- tion for the prevention and treatment of acne in the region. METHODS...OBJECTIVE： To analyze the correlation between ac- he and Northwest dryness syndrome in the Xinji- ang region to provide an epidemiological founda- tion for the prevention and treatment of acne in the region. METHODS： The correlations among acne, clinical syndromes of Northwest dryness syndrome, and Northwest dryness syndrome were evaluated using the syndrome fitness index and canonical correla- tion analysis. RESULTS： The ache group had a Northwest drynesssyndrome rate of 24.13%, and the control group 10.34% （χ2=7.733, P〈0.01）. There was no significant difference in the fitness index for acne and for the sub-syndromes of Northwest dryness syndrome （P〉 0.05）. The first canonical correlation coefficient was 0.5656 （P〈0.01）. The acne-dependent variable group had the largest damp-heat syndrome load （0.8709）, and the independent variable had the largest lung-heart-spleen pyretic dryness load （0.6766）. CONCLUSION： Northwest dryness syndrome is a risk factor for ache in the Xinjiang region. Exoge- nous dryness and endogenous damp are frequent- ly seen as subsyndromes in Northwest dryness syn- drome in acne patients in the region. Acne was cor- related with the damp-heat and lung-heart-spleen pyretic dryness sub-syndromes of Northwest dry- ness syndrome.展开更多
目的探讨阿法替尼治疗肺癌引起的皮肤不良反应类型和严重程度及其与抗肺癌疗效的相关性。方法对2016年12月至2018年1月在东南大学附属中大医院使用阿法替尼治疗的肺癌患者进行病例-病例对照研究。根据国际肿瘤化疗药物不良反应评价系统...目的探讨阿法替尼治疗肺癌引起的皮肤不良反应类型和严重程度及其与抗肺癌疗效的相关性。方法对2016年12月至2018年1月在东南大学附属中大医院使用阿法替尼治疗的肺癌患者进行病例-病例对照研究。根据国际肿瘤化疗药物不良反应评价系统4.0标准评估76例肺癌患者皮肤不良反应的类型及严重程度,按皮疹的严重程度分0级、1级、2级以上皮疹组。患者每隔3个月行胸部CT检查,根据实体肿瘤的疗效评价标准评估阿法替尼的抗肺癌疗效。采用Kruskal-Wallis H test秩和检验比较不同等级皮疹患者阿法替尼的抗肺癌疗效。结果76例肺癌患者中,44例疾病稳定或部分缓解,32例疾病进展。69例出现皮肤不良反应,包括42例(55.3%)痤疮样皮疹、35例(46.1%)甲沟炎、30例(39%)黏膜糜烂、8例(10.5%)毛发改变、6例(7.9%)手足综合征。0级皮疹组7例,有效3例;1级皮疹组19例,有效7例;2级以上皮疹组50例,有效34例,3组有效率差异有统计学意义(χ2=6.117,P=0.047),1级与2级以上皮疹组的有效率均高于0级组(均P<0.001),2级以上皮疹组的有效率高于1级组(P<0.001)。结论阿法替尼治疗肺癌可引起痤疮样皮疹、甲沟炎、黏膜糜烂、毛发改变和手足综合征等不同类型皮疹,皮疹的严重程度分级越高,阿法替尼的抗肺癌疗效越显著。展开更多
基金Supported by National Natural Science Foundation of China(2013)(No.81260518)
文摘OBJECTIVE： To analyze the correlation between ac- he and Northwest dryness syndrome in the Xinji- ang region to provide an epidemiological founda- tion for the prevention and treatment of acne in the region. METHODS： The correlations among acne, clinical syndromes of Northwest dryness syndrome, and Northwest dryness syndrome were evaluated using the syndrome fitness index and canonical correla- tion analysis. RESULTS： The ache group had a Northwest drynesssyndrome rate of 24.13%, and the control group 10.34% （χ2=7.733, P〈0.01）. There was no significant difference in the fitness index for acne and for the sub-syndromes of Northwest dryness syndrome （P〉 0.05）. The first canonical correlation coefficient was 0.5656 （P〈0.01）. The acne-dependent variable group had the largest damp-heat syndrome load （0.8709）, and the independent variable had the largest lung-heart-spleen pyretic dryness load （0.6766）. CONCLUSION： Northwest dryness syndrome is a risk factor for ache in the Xinjiang region. Exoge- nous dryness and endogenous damp are frequent- ly seen as subsyndromes in Northwest dryness syn- drome in acne patients in the region. Acne was cor- related with the damp-heat and lung-heart-spleen pyretic dryness sub-syndromes of Northwest dry- ness syndrome.
文摘目的探讨阿法替尼治疗肺癌引起的皮肤不良反应类型和严重程度及其与抗肺癌疗效的相关性。方法对2016年12月至2018年1月在东南大学附属中大医院使用阿法替尼治疗的肺癌患者进行病例-病例对照研究。根据国际肿瘤化疗药物不良反应评价系统4.0标准评估76例肺癌患者皮肤不良反应的类型及严重程度,按皮疹的严重程度分0级、1级、2级以上皮疹组。患者每隔3个月行胸部CT检查,根据实体肿瘤的疗效评价标准评估阿法替尼的抗肺癌疗效。采用Kruskal-Wallis H test秩和检验比较不同等级皮疹患者阿法替尼的抗肺癌疗效。结果76例肺癌患者中,44例疾病稳定或部分缓解,32例疾病进展。69例出现皮肤不良反应,包括42例(55.3%)痤疮样皮疹、35例(46.1%)甲沟炎、30例(39%)黏膜糜烂、8例(10.5%)毛发改变、6例(7.9%)手足综合征。0级皮疹组7例,有效3例;1级皮疹组19例,有效7例;2级以上皮疹组50例,有效34例,3组有效率差异有统计学意义(χ2=6.117,P=0.047),1级与2级以上皮疹组的有效率均高于0级组(均P<0.001),2级以上皮疹组的有效率高于1级组(P<0.001)。结论阿法替尼治疗肺癌可引起痤疮样皮疹、甲沟炎、黏膜糜烂、毛发改变和手足综合征等不同类型皮疹,皮疹的严重程度分级越高,阿法替尼的抗肺癌疗效越显著。
